RIPK1-IN-3

• UNSPSC Description:

  RIPK1-IN-3 (Example 38), a RIPK1 inhibitor, extracted from patent WO2018148626A1, possesses anti-inflammatory proprieties[1].

• Target Antigen:

  RIP kinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ripk1-in-3.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC(C2=CC3=NC(N)=NN3C=C2)=CN=C1OC)NC(C4=CC=CC=C4OC(F)(F)F)C

• Molecular Weight:

  472.42

• References & Citations:

  [1]Guo Junqing, et al. Aminotriazolopyridines as kinase inhibitors. WO/2018/148626A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2242677-36-5